Effects of Leflunomide and Methotrexate on RANKL and IL-17 in Collagen-Induced Arthritis in Rats

丁从珠,姚瑶,方芸,冯学兵,孙凌云,汪悦
DOI: https://doi.org/10.19460/j.cnki.0253-3685.2012.05.005
2012-01-01
Abstract:Objective To evaluate the effects of combined use of leflunomide and methotrexate on receptor activator of nuclear factor-κB liqand(RANKL) and interleukin-17(IL-17) in collagen-induced arthritis(CIA) in rats.Methods The CIA rat models were established and divided into 4 groups of MC(model control),L(leflunomide treated),M(methotrexate treated) and LM(treated with leflunomide and methotrexate).Serum RANKL and IL-17 were determined by ELISA.The results were compared to those in blank control group(BC).Results Serum levels of RANKL and IL-17 were significantly higher in group MC than those in group BC(P0.05).Compared with group MC,RANKL concentrations in groups of L,M and LM were obviously decreased(P0.05).Compared to group M,serum levels of RANKL and IL-17 in group LM were notably down-regulated(P0.05).Conclusion Combined use of leflunomide and methotrexate has a synergistic protection on CIA through down-regulating the serum level of RANKL and IL-17 in rats model.
What problem does this paper attempt to address?